Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
06/2012
06/07/2012WO2012075211A2 Combination therapy with a gallium complex
06/07/2012WO2012075210A2 Method for treating refractory cancer
06/07/2012WO2012075184A2 Cell lines that secrete anti-angiogenic antibody-scaffolds and soluble receptors and uses thereof
06/07/2012WO2012075111A1 Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
06/07/2012WO2012075075A2 Methods and systems for spatially identifying abnormal cells
06/07/2012WO2012074960A2 Fty720-derived anticancer agents
06/07/2012WO2012074926A1 Novel azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
06/07/2012WO2012074761A1 Oxazolo [5, 4 -b] pyridin- 5 -yl compounds and their use for the treatment of cancer
06/07/2012WO2012074754A1 Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors
06/07/2012WO2012074559A2 Treatment of non-proliferative cystic disease
06/07/2012WO2012074351A1 Tumour cytotoxic agent and methods thereof
06/07/2012WO2012074249A2 Novel purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition with inhibitory activity against raf kinase, containing same as active ingredient
06/07/2012WO2012074180A1 Novel tetraazacyclododecan-tetraone derivative or pharmaceutically acceptable salts thereof, and pharmaceutical composition containing same for preventing or treating cancer
06/07/2012WO2012074129A1 Peptide with safer secondary structure, peptide library, and production methods for same
06/07/2012WO2012074116A1 IMMUNOTHERAPY USING ALLO-NKT CELLS, CELLS FOR IMMUNOTHERAPY IN WHICH α CHAIN OF T-CELL RECEPTOR (TCR) GENE HAS BEEN REARRANGED TO UNIFORM Vα-Jα, AND BANKING OF NKT CELLS DERIVED FROM SAID CELLS
06/07/2012WO2012074097A1 Anti-cd33 antibody
06/07/2012WO2012074085A1 Marker for determination of sensitivity to triplet combination anti-cancer agent
06/07/2012WO2012074068A1 Method for producing hematopoietic stem cells using pyrazole compound
06/07/2012WO2012074067A1 Pyrazole compound having therapeutic effect on multiple myeloma
06/07/2012WO2012073985A1 Cytotoxicity-inducing therapeutic agent
06/07/2012WO2012073459A1 Tomm34 peptides and vaccines including the same
06/07/2012WO2012073375A1 Novel compound, and kinesin spindle protein inhibitor and application thereof
06/07/2012WO2012073217A1 Process for the preparation of morpholinyl anthracycline derivatives
06/07/2012WO2012073184A1 Quinolin-4 (1h) -one derivatives as inhibitors of phosphatidylinositol 3-kinases
06/07/2012WO2012073125A1 Tsh-conjugated nanocarrier for the treatment of thyroid cancer
06/07/2012WO2012073017A1 Substituted benzopyrazin derivatives as fgfr kinase inhibitors for the treatment of cancer diseases
06/07/2012WO2012072815A1 Anticancer fusion protein
06/07/2012WO2012072505A1 Volasertib alone or in combination with cytarabine for treating acute myeloid leukemia
06/07/2012WO2012072033A1 Substituted 2,3-phthalazinone compounds and use thereof
06/07/2012WO2012072019A1 Targeting human thymidylate kinase induces dna repair toxicity in malignant tumor cells
06/07/2012WO2012071980A1 Preparation method of α-imatinib mesylate
06/07/2012WO2012071684A1 Heterocyclic derivates，preparation processes and medical uses thereof
06/07/2012WO2012071649A1 Covalently dimerized bivalent binding agents
06/07/2012WO2012051339A3 Methods and compositions for treating respiratory conditions using platelet enriched plasma
06/07/2012WO2012048446A8 New use of chemical ingredients in cynomorium as phytoestrogen
06/07/2012WO2012034132A3 Inhibitors of human ezh2, and methods of use thereof
06/07/2012WO2012028310A3 Compositions comprising a taxane for coating medical devices
06/07/2012WO2012027462A3 Compositions and methods for treating neoplasia
06/07/2012WO2012027274A3 Compositions and methods for imaging
06/07/2012WO2012022496A3 Method for killing tumor stem cells
06/07/2012WO2012020123A9 Neuropilin as a biomarker for bevacizumab combination therapies
06/07/2012WO2011133584A8 Nucleic acid compounds for inhibiting hras gene expression and uses thereof
06/07/2012WO2011023986A8 Kinase inhibitors
06/07/2012US20120144510 Treatment of astrocytes-tumor cells inhibitors of endothelin receptors
06/07/2012US20120142941 Composition for alleviating ultraviolet radiation-induced damage
06/07/2012US20120142784 Lysine-specific demethylase 1(lsd1) is a biomarker for breast cancer
06/07/2012US20120142780 Use of 2,5-dihydroxybenzenesulfonic acid in the manufacturing of medicines, applicable to the treatment of angiodependent diseases
06/07/2012US20120142778 Microbiological method for synthesizing cinnamoyl amide derivatives of amino acids
06/07/2012US20120142770 Pharmaceutical compositions of hdac inhibitors and chelatable metal compounds, and metal-hdac inhibitor chelate complexes
06/07/2012US20120142766 Substituted 1,3-dioxanes and their uses
06/07/2012US20120142761 Oligonucleotides or their functional homologues, a composition comprising the same and a method of treating b cell neoplasm
06/07/2012US20120142758 Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
06/07/2012US20120142757 RNAi Modulation of AHA and Therapeutic Uses Thereof
06/07/2012US20120142753 Diagnosis and treatment of adrenocortical tumors using human microrna-483
06/07/2012US20120142751 Methods for the production of biliverdin
06/07/2012US20120142749 Solid salt forms of a pyrrole substituted 2-indolinone
06/07/2012US20120142745 Novel phenyl oxadiazole derivatives as sphingosine 1-phosphate (s1p) receptor modulators
06/07/2012US20120142744 Novel complexes of fatty acid esters of polyhydroxyalkanes and pyridine carboxy derivatives
06/07/2012US20120142742 Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
06/07/2012US20120142741 Pharmaceutical compositions for the treatment of cancer
06/07/2012US20120142740 Novel alkene derivatives as sphingosine 1-phosphate (s1p) receptor modulators
06/07/2012US20120142739 Novel oxadiazole derivatives as sphingosine 1-phosphate (s1p) receptor modulators
06/07/2012US20120142736 Novel pyridine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
06/07/2012US20120142735 Disubstituted [4-(5-aminomethyl-phenyl)-piperidin-1-yl]- 1h-indol-3-yl]-methanones
06/07/2012US20120142734 Methods for treating tumors with thalidomide
06/07/2012US20120142733 4-substituted-cyclohexylamino-4-piperidinyl-acetamide antagonists of ccr2
06/07/2012US20120142732 Heteroaryls and uses thereof
06/07/2012US20120142730 Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
06/07/2012US20120142729 KAT ll INHIBITORS
06/07/2012US20120142726 Pharmaceutical compositions comprising 3,4-dihydroisoquinolin-2(1h)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
06/07/2012US20120142724 OXAZOLO[5-4-b]PYRIDIN-5-YL COMPOUNDS
06/07/2012US20120142722 Conjugates of cytotoxic drugs
06/07/2012US20120142721 Small molecule inhibitors of polynucleotide kinase/phosphatase, poly(adp-ribose) polymerase and uses thereof
06/07/2012US20120142716 4-pyrimidinesulfamide derivative
06/07/2012US20120142711 Acid-labile trigger units
06/07/2012US20120142709 Substituted pyridinone-pyridinyl compounds
06/07/2012US20120142708 Substituted pyridine urea compounds
06/07/2012US20120142703 New combination therapy in treatment of oncological and fibrotic diseases
06/07/2012US20120142702 Integrin-linked kinase inhibitors
06/07/2012US20120142701 Compounds and methods for the treatment of proliferative diseases
06/07/2012US20120142697 Salt forms of 4-(4-Methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino)phenyl]-benzamide
06/07/2012US20120142696 Substituted indole/indazole-pyrimidinyl compounds
06/07/2012US20120142690 Substituted piperidines
06/07/2012US20120142689 Serotonin reuptake inhibitors
06/07/2012US20120142685 Organic compounds
06/07/2012US20120142683 Pyrimidine substituted purine compounds as kinase (s) inhibitors
06/07/2012US20120142681 Heterocyclic hydrazone compounds
06/07/2012US20120142680 Heteroalkyl linked pyrimidine derivatives
06/07/2012US20120142679 Novel 2,3-dihydro-1h-imidazo(1,2-a)pyrimidin-5-one derivatives, preparation thereof, and pharmaceutical use thereof
06/07/2012US20120142678 Novel compound useful for the treatment of degenerative and inflammatory diseases
06/07/2012US20120142677 Pyrrolidine Compounds Which Modulate The CB2 Receptor
06/07/2012US20120142676 Oxathiazine and dithiine oxides as inhibitors of sulfhydryl-dependent biomolecules
06/07/2012US20120142675 Methods for Treating Diseases of the Retina
06/07/2012US20120142673 Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors
06/07/2012US20120142671 Benzamides and nicotinamides as syk modulators
06/07/2012US20120142666 Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor
06/07/2012US20120142664 Novel benzyl azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
06/07/2012US20120142662 Novel azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
06/07/2012US20120142661 Novel oxime azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
06/07/2012US20120142660 Aminopyrimidines useful as kinase inhibitors
1 ... 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 ... 2211